← Leaderboards
Fred Stephen Sarfo
Medical University Of South Carolina
$4,523,537
Attributed
$9,695,187
Total exposure
8
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,695,187 · 8
By mechanism
R01$7,165,844 · 4
U01$1,442,972 · 1
R21$619,006 · 2
D43$467,365 · 1
Top collaborators
- Bruce Ovbiagele18 shared
- Yvonne Commodore-Mensah5 shared
- Solomon Fiifi Ofori-Acquah5 shared
- Dike Bevis Ojji5 shared
- Prisca Olabisi Adejumo2 shared
- Obiageli Eunice Nnodu2 shared
- Emmanuel K Peprah2 shared
Most similar at Medical University Of South Carolina
Same institution · by research overlap
- Don C Rockey$16,593,570
- Brent M Egan$2,811,640
- Julie Chao$9,369,252
- Donald R. Menick$17,263,987
- Cynthia F. Wright$11,018,594
Others in their field
Top investigators on “Ghana”
- Stephen Lev Hoffman · Sanaria, Inc.$15,767,843
- Francois Dabis · Adera$10,883,220
- Darby Jack · Columbia University Health Sciences$9,056,739
- Awewura Jacob Kwara · Miriam Hospital$8,351,735
- Michael Cappello · Yale University$7,066,687
- Julie Makani · Muhimbili University/ Allied Hlth Scis$6,453,988
Research focus
GhanaResourcesCountryStrokeAdoptionEvidence BaseHospitalsProgramsImplementation StrategyStandardizationPoliciesMortalityEventCaringPharmaceutical PreparationsPrevalenceCessation Of LifeAfrica South Of The SaharaAfricaRecurrenceHypertensionRisk FactorsIncidenceHybrids
Grant awards (30)
CiLostAzol for pReventIon of recurrent sTroke in Africa (CLARITY-Africa)$420,571
R01 · FY2025 · NS
Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment II Study$419,317
R01 · FY2025 · NS
The ADHINCRA Study: Addressing HypertensIoN Care in AfRicA$383,681
R01 · FY2025 · HL
Ghana-SPARCO: Ghana Sickle Pan-African Research Consortium$350,302
U01 · FY2025 · HL · contact PI
Sickle Pan Africa Research Consortium TRAINing (SPARC- TRAIN) Program$238,350
D43 · FY2025 · TW
Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment II Study$91,783
R01 · FY2025 · NS
The ADHINCRA Study: Addressing HypertensIoN Care in AfRicA$90,000
R01 · FY2025 · HL
CiLostAzol for pReventIon of recurrent sTroke in Africa (CLARITY-Africa)$88,614
R01 · FY2025 · NS
The ADHINCRA Study: Addressing HypertensIoN Care in AfRicA$81,540
R01 · FY2025 · HL
The ADHINCRA Study: Addressing HypertensIoN Care in AfRicA$40,000
R01 · FY2025 · HL
The ADHINCRA Study: Addressing HypertensIoN Care in AfRicA$648,073
R01 · FY2024 · HL
Phone-based Interventions under Nurse Guidance after Stroke II (PINGS II)$548,929
R01 · FY2024 · HL
CiLostAzol for pReventIon of recurrent sTroke in Africa (CLARITY-Africa)$525,734
R01 · FY2024 · NS
Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment II Study$495,766
R01 · FY2024 · NS
Ghana-SPARCO: Ghana Sickle Pan-African Research Consortium$331,151
U01 · FY2024 · HL · contact PI
Sickle Pan Africa Research Consortium TRAINing (SPARC- TRAIN) Program$229,015
D43 · FY2024 · TW
Phone-based Interventions under Nurse Guidance after Stroke II (PINGS II)$571,425
R01 · FY2023 · HL
Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment II Study$511,100
R01 · FY2023 · NS
Ghana-SPARCO: Ghana Sickle Pan-African Research Consortium$268,617
U01 · FY2023 · HL · contact PI
Phone-based Interventions under Nurse Guidance after Stroke II (PINGS II)$569,472
R01 · FY2022 · HL
Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment II Study$532,166
R01 · FY2022 · NS
Ghana-SPARCO: Ghana Sickle Pan-African Research Consortium$265,269
U01 · FY2022 · HL · contact PI
Phone-based Interventions under Nurse Guidance after Stroke II (PINGS II)$565,153
R01 · FY2021 · HL
Ghana-SPARCO: Ghana Sickle Pan-African Research Consortium$227,633
U01 · FY2021 · HL · contact PI
Phone-based Interventions under Nurse Guidance after Stroke II (PINGS II)$582,520
R01 · FY2020 · HL
Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment (SMAART)$147,022
R21 · FY2019 · NS
Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment (SMAART)$160,406
R21 · FY2017 · NS
Evaluation of Vascular Event Risk while on Long-term Antiretroviral Suppressive Treatment (EVERLAST)$141,602
R21 · FY2017 · TW
Evaluation of Vascular Event Risk while on Long-term Antiretroviral Suppressive Treatment (EVERLAST)$7,999
R21 · FY2017 · TW
Evaluation of Vascular Event Risk while on Long-term Antiretroviral Suppressive Treatment (EVERLAST)$161,977
R21 · FY2016 · TW